Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals productsBusiness Overview: Company is a subsidiary of Fredun Group. It manufactures pharmaceutical and allopathic formulations viz. tablets, syrups, capsules, and ointments. Product basket includes multiple therapeutic classes such as anti-diabetics, anti-retroviral and anti-hypertensive. Company also ventured into manufacturing of…
Fredun Pharmaceuticals has released the audio recording of its Q1 FY26 Earnings Conference Call. This recording, now accessible on the company's website, provides a comprehensive overview of the financial results for the quarter. Shareholders and potential investors can use this resource to gain direct insights into the company's operational performance...
Fredun Pharmaceuticals has made available the audio recording of its Q1 FY25 earnings conference call. This call discussed the financial results for the quarter ended June 30, 2025. The recording is now accessible on the company's website, allowing investors and stakeholders to review the detailed discussions regarding the company's recent...
Fredun Pharmaceuticals reported strong Q1 FY26 results with Net Profit increasing 63.82% to ₹6.77 Cr, and Total Income rising 52.08% to ₹119.86 Cr. EBITDA also grew by 62.15% to ₹16.99 Cr. This reflects successful execution of their growth strategy and strong demand for their diversified product range. The company's order...
The company's board has approved the financial results for the quarter ended June 30, 2025. Additionally, following input from its Nomination and Remuneration Committee, the board appointed two new independent directors: Mr. Anshu Agarwal and Ms. Sonal Desai. Both have been appointed for a five-year term, effective immediately, pending shareholder...
The company has announced the outcomes of a recent board meeting. The financial results for the quarter were adopted. Additionally, the Board, following the Nomination and Remuneration Committee's proposal, appointed Mr. Anshu Agarwal and Ms. Sonal Desai as new Independent Directors for five-year terms. These appointments, awaiting shareholder approval, aim...
